Wescott Financial Advisory Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-8,914
Closed -$250K 203
2026
Q1
$250K Sell
8,914
-4,752
-35% -$127K 0.02% 171
2025
Q4
$340K Sell
13,666
-1,229
-8% -$31K 0.03% 152
2025
Q3
$380K Sell
14,895
-2,176
-13% -$53.7K 0.03% 138
2025
Q2
$414K Buy
17,071
+1,778
+12% +$41.5K 0.04% 129
2025
Q1
$388K Sell
15,293
-1,088
-7% -$28.5K 0.04% 126
2024
Q4
$435K Buy
16,381
+864
+6% +$23.4K 0.05% 123
2024
Q3
$449K Buy
15,517
+7,522
+94% +$219K 0.05% 122
2024
Q2
$224K Buy
+7,995
New +$220K 0.03% 157
2023
Q4
Sell
-6,433
Closed -$213K 168
2023
Q3
$213K Sell
6,433
-334
-5% -$11.8K 0.04% 147
2023
Q2
$248K Sell
6,767
-1,753
-21% -$68.2K 0.04% 142
2023
Q1
$348K Buy
8,520
+2,853
+50% +$123K 0.08% 119
2022
Q4
$290K Buy
+5,667
New +$272K 0.06% 125
2022
Q3
Sell
-17,307
Closed -$907K 142
2022
Q2
$907K Buy
17,307
+2,977
+21% +$152K 0.25% 57
2022
Q1
$742K Buy
+14,330
New +$744K 0.19% 66

Other funds holding PFE

Wescott Financial Advisory Group's PFE Position: Q2 2026 in Review

Wescott Financial Advisory Group sold out of Pfizer (PFE) in Q2 2026, closing a stake of 8,914 shares — an estimated $250K sold.

Wescott Financial Advisory Group first reported a position in PFE in Q1 2022 and held it in 14 quarters. The position peaked at $907K in Q2 2022. 2,820 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Wescott Financial Advisory Group reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
  • Wescott Financial Advisory Group sold 8,914 Pfizer shares in Q2 2026, an estimated $250K.
  • Wescott Financial Advisory Group first reported a position in Pfizer in Q1 2022 and held it in 14 quarters.
  • Wescott Financial Advisory Group's Pfizer position peaked at $907K in Q2 2022.
  • 2,820 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Wescott Financial Advisory Group's 13F filing for Q2 2026, filed 4 Aug 2026.